FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
Pharma Deals, Investments and M&As in March 2018
If
the first two months of 2018 saw pharma and biotech firms receive more money
than what
al
India-China border tension may impact billion dollar pharma deal; AZ’s investors worry as key cancer drug fails trial
This week in Phispers, we analyze the
situation at AstraZeneca, where its much anticipated lung canc